Enlivex

@DaveWeb3Saint One Ticker. Two Engines. $ENLV

@Enlivex The Direction is getting so clear

Today Enlivex announced four simultaneous strategic actions: 1/ $21 Million debt financing with an institutional investor, convertible at $2.69175, a 264% premium to the stock's closing price. 2/ 3 Billion RAIN tokens acquired at $0.0033 via a $10 Million partial option exercise. 3/ The duration of our option to acquire up to an additional 272 Billion RAIN tokens at $0.0033 was extended through December 31, 2027. 4/ A $20 Million share repurchase program was approved by the Board. Four moves. One direction. $ENLV

full press release: investors.enlivex.com/press-releases…

source: oaaction.unc.edu/oa-module/oa-p…

Today, the FDA cleared our IND application to initiate a Phase 2b clinical trial of Allocetra in patients with age-related primary knee osteoarthritis. 32.5 million Americans live with the condition today. 78 million are projected to by 2040. There are currently no approved effective durable treatment for osteoarthritis. That is the gap Allocetra is built to close. $ENLV

Every transaction on @Rain__Protocol fuels the Enlivex treasury engine. The protocol allocates 2.5% of total market volume to a programmatic buyback-and-burn mechanism, embedding supply contraction directly into its economic design. This creates an automatic deflationary layer at the protocol level. By designating RAIN as a primary reserve asset, Enlivex incorporates this programmatic infrastructure into its corporate treasury within a regulated Nasdaq framework. As forecasting volumes expand, the amount allocated to buybacks increases proportionally, linking treasury exposure to the broader adoption of prediction markets. This structure provides shareholders with access to the economic upside of the forecasting sector through a compliant equity vehicle anchored by a clinical-stage biotechnology foundation. $ENLV

The @Rain__Protocol is a decentralized prediction markets infrastructure built on @arbitrum, enabling developers to create their own prediction market platforms and applications via a modular SDK built for AI agents. Through our $918M fixed-price option in Rain token, $ENLV shareholders have structured, non-dilutive exposure to the projected growth of the prediction markets sector. Rather than holding a passive reserve asset, Enlivex has anchored its treasury in a protocol whose value is mechanistically tied to the expansion of the entire global prediction markets industry.

sources: 1/ nature.com/articles/s4159… 2/mordorintelligence.com/industry-repor…

Osteoarthritis is a $7B+ global market affecting over 300 million people. That is more than 3.6% of the world's population living with chronic inflammation, pain, and reduced mobility. Most current therapies manage symptoms and do not address the underlying immune imbalance driving disease progression. Allocetra is a cell therapy developed by Enlivex to reprogram dysfunctional macrophages and restore joint homeostasis at the source of inflammation. This is a key component of the quality longevity mission. True longevity is impossible without mobility. By resolving the chronic inflammation that traps 300 million people in a sedentary cycle, Allocetra restores the mechanical foundation required for active, healthy aging. Allocetra is the scientific foundation of $ENLV. A differentiated clinical program targeting an underserved population within a multi-billion-dollar market, consolidated under a single Nasdaq ticker. $ENLV

source: falconx.io/newsroom/from-…

Prediction markets are no longer a niche experiment. They are becoming the new infrastructure for global information, growing faster than almost any other asset class. According to a recent report from @FalconXGlobal, annual volumes in the forecasting sector are projected to grow from $64B in 2025 to over $325B in 2026. Through our strategic deal with @Rain__Protocol, we’ve secured a capital layer that includes programmatic yield and aggressive anti-dilution protection, to engineer the first-ever corporate treasury built on the prediction market sector. While others are betting on outcomes, we have created a treasury that captures the growth of the entire industry through a single, regulated Nasdaq ticker.

A new standard. A new logo. Introducing the world’s first healthspan-wealthspan company. $ENLV

After months of hard work, we are proud to unveil the new Enlivex website, the home for everything we are building. I have spent decades navigating the capital-intensive cycles of the life sciences. If my tenure leading PROLOR through a $590 million exit and partnering with Pfizer taught me anything, it is that breakthrough innovation must be matched by a resilient corporate structure. The mission at Enlivex is quality longevity. Not just living longer, but moving, functioning, and living better. Allocetra targets osteoarthritis, a condition disabling 300 million people worldwide where the current standard of care is structurally failing. That mission required a financing architecture equal to it. We chose to anchor our treasury in the RAIN protocol because of the unique capital structure we were able to engineer. By obtaining an exclusive fixed-price option for up to $918M of RAIN, we've secured a long-term foundation to fund our clinical work. This is an innovative financing model that gives our shareholders exposure to one of the fastest-growing sectors in the world while we advance Allocetra. You can now explore the full vision over on our new website: enlivex.com

We have spent the last year pioneering a first-of-its-kind model at Enlivex, and today we’re unveiling its new home. Our core mission is to restore quality of life for the 300 million people suffering from osteoarthritis. We are currently advancing Allocetra, a therapy designed to reprogram the immune system and restore quality of life. To fund this mission, we've engineered the world's first ever prediction markets treasury. By anchoring our reserves in the RAIN protocol, we have created an institutional-grade wrapper that gives investors direct exposure to the upside of global prediction markets. As the forecasting industry matures, our treasury is structurally positioned to benefit from RAIN's autonomous, programmatic economics. This provides a unique opportunity to access a dual-engine growth model: the upside of prediction markets, and the clinical milestones of a breakthrough therapy, in a single ticker. You can now visit our new website to explore the full model: enlivex.com $ENLV